ArticleBMC complementary medicine and therapies2025
Analysis of the effect of the Xianglian capsule on patients with diarrhea after cholecystectomy: a protocol for a single-center, randomized controlled trial.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The pharmacological effects and therapeutic potential of flavonoids in digestive diseases.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionDiarrhea is a common complication in patients after cholecystectomy. In China, tens of millions of patients experience diarrhea every year after cholecystectomy, which results in long-term pain in patients. Traditional Chinese medicine is a national treasure and has made great contributions to human health throughout the long history of the Chinese nation. However, as a classic ready-for-use traditional Chinese medicine, the exact clinical efficacy of the Xianglian preparation needs further observation. This article presents the protocol of a single-center, randomized controlled trial to evaluate the clinical efficacy of Xianglian capsules in patients with diarrhea after cholecystectomy. METHODS AND ANALYSIS: This study was conducted in the Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Guangdong Medical University, following the recommendations of the current SPIRIT and CONSORT statements. We will recruit 90 patients who have developed diarrhea after cholecystectomy and randomize them 1:1 into the observation and control groups. The control group was given starch placebo capsules, and the observation group was given Xianglian capsules. Patient diarrhea-related indicators were collected at baseline and 5 days postdose. We will also collect patients' intestinal inflammation-related indicators and fecal microbial samples to analyze the possible mechanism of action of drugs. DISCUSSION: This study will clarify the clinical effects of the Xianglian preparation on patients with diarrhea after cholecystectomy, provide evidence-based evidence, and promote the development and application of this classic prescription.
trial registrationhttp://www.chictr.org.cn . TRIAL NUMBER: ChiCTR2200061854. Registered on 04 July 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.